Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
FDA Advisory Committee Votes Unanimously to Confirm Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Early Alzheimer's Disease
BioArctic AB‘s partner Eisai announced that the US Food and Drug Administration’s (FDA) Peripheral and […]
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Great Britain
Eisai and Biogen announced today that Eisai has submitted a Marketing Authorization Application (MAA) for […]
Health Canada Accepts New Drug Submission for lecanemab as Treatment for Early Alzheimer's Disease
BioArctic AB’s partner Eisai announced today that Health Canada has accepted a New Drug Submission […]
Eisai Enters Into Joint Development Agreement with Blissbio for Antibody Drug Conjugate BB-1701
Eisai announced today that it has entered into a joint development agreement with Bliss Biopharmaceutical […]
U.S. Veterans' Health Administration (VHA) Provides Coverage of LEQEMBI™ (lecanemab-irmb) for Veterans Living with Early Stages of Alzheimer's Disease
BioArctic AB’s partner Eisai announced today that the U.S. Veterans Health Administration (VHA) is providing […]
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Eisai and Biogen announced today that the US Food and Drug Administration (FDA) has accepted […]
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration
Eisai and Biogen announced today that the Biologics License Application (BLA) for lecanemab, an investigational […]
BioArctic: Lecanemab Receives Priority Review Status in Japan
BioArctic AB’s partner Eisai has announced that the application for manufacturing and marketing approval for […]
European Medicines Agency accepts Marketing Authorization Application for lecanemab as treatment for early Alzheimer's disease
BioArctic AB‘s partner Eisai have announced that the European Medicines Agency (EMA) has accepted a […]
Eisai Submits Marketing Application for lecanemab for Alzheimer's
BioArctic AB’s partner Eisai announced today that Eisai has submitted a marketing authorization application for […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more